Aging microglia, the immune cells of the brain that protect it by fighting infections and clearing debris, may mount a weaker immune response than younger microglia, according to a study that used lab-grown cells collected from mouse pups. Although both young and old microglia react to inflammation, they appear to…
Approximately two-thirds of Parkinson’s disease patients may experience paranoia and unusual sensations, including visual hallucinations, according to a new study from the U.K. People with Parkinson’s may have paranoid thoughts or unfounded fears, as well as abnormal sensory experiences, the study found. Further, many of the individuals who had…
U.S. researchers have identified, as a potential therapeutic target in Parkinson’s disease, a protein that controls part of the function of LRRK2 — a protein known to be overactive in Parkinson’s, including in patients without mutations in its coding gene. This discovery, made using cell and mouse models of…
C2N Diagnostics and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are teaming up to study how Parkinson’s disease and similar neurodegenerative conditions overlap with Alzheimer’s disease. With a grant in the amount of more than $1.5 million from MJFF, researchers at C2N will identify and…
A mobile application that detects a person’s natural walking pace and provides real-time, beat-synchronized music for at-home rehabilitation improved walking in Parkinson’s disease patients, both during daily activities and in tests without music cues, a study found. The study, “Gait ecological assessment in persons with Parkinson’s disease engaged…
Aspen Neuroscience has completed dosing the first two groups of patients in ASPIRO, an ongoing Phase 1/2a clinical trial that’s testing the safety and tolerability of ANPD001, an investigational cell therapy for Parkinson’s disease. Patients with moderate to severe Parkinson’s who have so far received ANPD001, which uses…
BlueRock Therapeutics said it is progressing its investigational cell therapy, bemdaneprocel, into a Phase 3 clinical trial set to begin in the first half of 2025. The trial, named exPDite-2, will assess the safety and efficacy of the treatment for moderate Parkinson’s disease. This decision comes after positive…
Levodopa, a standard Parkinson’s disease medication, may help alleviate muscle stiffness, one of the condition’s characteristic motor symptoms, by slowing the speed of electrical signals sent to muscles during movement, particularly when muscles are required to stretch quickly, a small study reports. Using a robotic device to help measure…
The number of copies of mitochondrial DNA in the blood of people with Parkinson’s disease are not a biomarker of poorly functioning mitochondria — the source of energy that powers cells — but may instead reflect immune responses that occur outside the brain, a study found. The findings, which…
The first patient in a Phase 2 clinical study testing BIA 28-6156 — a small molecule in the pipeline at Bial for treating Parkinson’s disease in people with mutations in the GBA1 gene — has completed the full dose regimen, the company announced. The goal of the study,…
Get regular updates to your inbox.
